ADC Review / Journal of Antibody-drug Conjugates (ISSN: 2327-0152) is an international publication combining professional social media with an online-only, hybrid open-access, peer reviewed journal.
The Journal aims to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers.
Key information includes peer-reviewed articles, news features, discussions, blogs, and a knowledge center offering the latest and most relevant information about Antibody Drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments.
The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.
ADC Review / Journal of Antibody-drug Conjugates is seeking funding partners to help with the ongoing development of the journal and affiliated projects.
See more updates for ADC Review / Journal of Antibody-drug Conjugates
If you currently work at this organization, click the “Do you work here?” button to request editing privileges.
This SponsorPitch page is about ADC Review / Journal of Antibody-drug Conjugates and contains information about this organization's sponsorship activity, sponsorship decision makers and sponsorship preferences. This page is not endorsed by or affiliated with ADC Review / Journal of Antibody-drug Conjugates, though it may be actively managed and updated by company representatives. If you currently work at this organization, click the Manage Sponsor button to request management privileges. All trademarks, service marks and copyrights are property of their respective owners.